Daewha Pharm wins Korean patent for amodipine

Published: 2008-06-16 06:56:00

Updated: 2008-06-16 06:56:00

Daewha Pharm announced in its regulatory filing on June 11 that it acquired a Korea patent for manufacturing film-coated granules containing amodipine or S-amlodipine salts and excipients.

S-amlodipine salts are said to be effective in the prevention and treatment of hypertension.

The firm ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK